X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds from the proposed financed will focus on the development of LB-102, which is an N-methylated analogue of amisulpride under development to treat schizophrenia.
Lead Product(s): N-Methyl Amisulpride
Therapeutic Area: Psychiatry/Psychology Product Name: LB-102
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing January 24, 2024
Details:
LB-102, a more lipophilic version of amisulpride, was designed to improve on amisulpride’s notoriously poor membrane (BBB) permeability while matching amisulpride’s binding affinity to the D2/D3 and 5HT7 receptors (critical to the treatment of schizophrenia).
Lead Product(s): N-Methyl Amisulpride
Therapeutic Area: Psychiatry/Psychology Product Name: LB-102
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2022
Details:
LB-102, or N-methyl amisulpride, is a patented derivative of amisulpride, a dopamine/5-HT7 antagonist successfully used to treat schizophrenia in Europe for decades.
Lead Product(s): N-Methyl Amisulpride
Therapeutic Area: Psychiatry/Psychology Product Name: LB-102
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2021
Details:
Proceeds to enable the Company’s continued clinical development of LB-102 for the treatment of schizophrenia.
Lead Product(s): N-Methyl Amisulpride
Therapeutic Area: Psychiatry/Psychology Product Name: LB-102
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Financing September 25, 2020
Details:
LB-102 was well-tolerated up to 150 mg/day. Plasma concentrations of LB-102 were ~2.5 times greater than published values of amisulpride at the same dose, suggesting LB-102 could be dosed substantially lower than amisulpride.
Lead Product(s): Amisulpride
Therapeutic Area: Psychiatry/Psychology Product Name: LB-102
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2020
Details:
The ongoing study aims to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of LB-102 in healthy volunteers.
Lead Product(s): Amisulpride
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
